

Page numbers in **bold** indicate the start of the main discussion of the topic. Page numbers followed by “f” or “t” refer to the page location of figures and tables, respectively, and a “v” indicates a video on the DVD. Numbers containing “e-” followed by a number (e.g., 91e-3) refer to pages in the e-chapters on the DVD.

- A**
- AA amyloidosis, **723**
 characteristics of, 719
 clinical features of, 720t, 723, 1835t
 diagnosis of, 720f, 1845
 etiology of, 723
 incidence of, 723
 pathogenesis of, 1845
 treatment of, 723, 1845
- AAG (autoimmune autonomic ganglionopathy), 2642
- AAS abuse. *See* Anabolic-androgenic steroid (AAS) abuse
- AAV (adeno-associated virus), 91e-1t, 91e-3, 214e-4, 214e-9
- AAV-LPL, 91e-3
- AAV-RPE65, 91e-3
- Abacavir
 adverse effects of
 genetic considerations in, 373e-7, 373e-8t, 378, 1241
 in HIV infection, 1260, 1274t, 1277
 hypersensitivity, 382, 1277. *See also* Drug-induced hypersensitivity syndrome (DIHS)
 genetic variations in response to, 38, 39t, 41
 for HIV infection, 1274t, 1277–1278
 molecular structure of, 1276f, 1277
 resistance to, 1278, 1279f
- A band, of sarcomere, 265e-5
- Abatacept, 2146t, 2147
- ABCA1 deficiency (Tangier disease), 1443, 2445, 2681
- ABCA1 gene, 291e-2
- ABCB11 gene mutations, 284
- ABCDEs, in nevi evaluation, 494
- ABCD rule, 76e-6
- ABCG5/G8 hemitransporter, 2075
- Abciximab
 action of, 746f, 748–749
 adverse effects of, 727, 727t, 749
 discontinuation before lumbar puncture, 443e-1
 dosage of, 749
 genetic variations in response to, 277t, 743t
 indications for, 749
 for myocardial infarction, 1598t
 in PCI, 296e-1
 pharmacology of, 749t
- Abdomen
 paradoxical movement of, 47e-3
 physical examination of, 286, 1443
- Abdominal aortic aneurysm. *See* Aortic aneurysm, abdominal
- Abdominal pain, **103**
 in acute intermittent porphyria, 2526
 in appendicitis, 1986–1987, 1987t
 approach to the patient, 103t, 105–107
 differential diagnosis of, 106t, 1876, 1877t
 in Fabry's disease, 432e-1
 history in, 106
 imaging in, 106–107
 in immunocompromised patients, 105
 in intestinal ischemia, 1979–1980
 in intestinal obstruction, 1983
 in irritable bowel syndrome, 1965
 in malabsorption syndromes, 1946t
 mechanisms of
 abdominal wall disorders, 104–105
 mechanical obstruction, 103–104, 104t
 metabolic, 104t, 105
 neurogenic, 105
 neurologic/psychiatric, 104t
 parietal peritoneal inflammation, 103, 104t
 toxic, 104t
 vascular disturbances, 104
 in pancreatitis, 106, 106t, 2092, 2099, 2101
 in pelvic inflammatory disease, 877
 in peptic ulcer disease, 1918
 in peritonitis, 846, 1989
 physical examination in, 106
 in pregnancy, 50
 referred, 105, 105t
- Abdominal paracentesis, 483e-1v
- Abdominal reflexes, 2539
- Abdominal swelling/distention, **285**, 286f, 1983.
See also Ascites
- Abdominal wall disorders, 104–105
- Abdominogular reflex, 1444
- Abducens nerve, 2537
- Abducens nerve palsy, 209
- Abducens nerve paresis, 208
- Abduction and external rotation test, 1647
- A β amyloidosis, 719
- A β fibers, 87
- Abetalipoproteinemia (acanthocytosis), **2444**
 clinical features of, 269, 436e-4f, 2444
 genetic considerations in, 2444, 2630
 pathophysiology of, 1939, 2444, 2630
 peripheral blood smear in, 81e-4f
 small-intestinal mucosal biopsy in, 1939, 1940t
 treatment of, 96e-8, 2444
 vitamin E deficiency in, 96e-8
- A β ₂M amyloidosis, 719, 720t, 724. *See also* Amyloidosis
- A β peptides, 2600, 2600f
- A β /tau protein, 172t, 175
- ABI (ankle-brachial index), 1616, 1643
- Abiotrophia* spp., 821, 971
- Abiraterone, 103e-15, 586
- ABL gene mutations, 101e-3, 101e-3t, 689
- ABO blood group system, 138e-1
- Abortion
 infections following, 1165
 septic, 1060, 1099
 spontaneous, 83e-4
 threatened, 338
- ABPA. *See* Allergic bronchopulmonary aspergillosis (ABPA)
- Abruptio placenta, 46, 49
- Abscess
 anorectal, 1977–1978, 1977f
 brain. *See* Brain abscess
 epidural. *See* Epidural abscess
 formation of, 145e-10
 intraabdominal. *See* Intraabdominal abscess/infections
 periapical, 236
 peritonsillar, 233, 235, 1097
 perivalvular, 818
 retropharyngeal, 235
 subperiosteal, 231
 tuboovarian, 1089, 1099
- Abscopal effect, 412
- Absence seizures, 2543
- Absent (vanishing) testis syndrome, 2353
- Absolute risk reduction, 26
- Absorption
 of antibacterial drugs, 934–935
 of carbohydrates, 1937, 1937t
 disorders of. *See* Malabsorption syndromes of drugs, 33–34
 of lipids, 62f, 1935–1936, 1935t
 nutrient, **1933**
 of proteins, 1937
- Absorption spectrum, 385
- Abstract thought, assessment of, 2537
- Abulia, 1771, 2574f
- Acalculia, 179
- Acamprosate, 2059, 2728
- Acanthamoeba* spp., 245e-4t, 1367
- Acanthamoeba* spp. infections
 chronic meningitis, 908t
 clinical features of, 1367
 diagnosis of, 245e-4t, 245e-6t, 1367–1368
 epidemiology of, 245e-4t
 keratitis, 1368, 1368f
 meningoencephalitis, 896
 treatment of, 1368
- Acanthocytes, 81e-1
- Acanthocytosis. *See* Abetalipoproteinemia
- Acantholysis, 370
- Acanthosis, 372e-24t, 387, 1654f
- Acanthosis nigricans
 anti-insulin receptor antibodies in, 2348
 in diabetes mellitus, 2405, 2430
 disorders associated with, 76e-15, 359, 360t
 in gastric cancer, 535
 hyperpigmentation in, 76e-16f, 359
 in metabolic syndrome, 2452
 in obesity, 415e-6
- Acarbose, 1926, 2414t
- Accelerated idioventricular rhythm, 278e-12f, 1609
- Accelerated junctional rhythm, 1480–1481, 1609
- Accessory genome, 972
- Accessory pathways (APs)
 atrial fibrillation and, 1483
 in AV reentry tachycardia, 1481
 definition of, 1481
 in preexcited tachycardias, 1482, 1483f
 treatment of, 1482–1489
 in Wolff-Parkinson-White syndrome, 1481.
See also Wolff-Parkinson-White syndrome
- Accidents
 deaths from, 6e-1t, 6e-2f, 56t
 in health care industry, 12e-1, 12e-1f
- ACE. *See* Angiotensin-converting enzyme (ACE)
- Acebutolol, 473e-9t, 1480t, 1589t
- Aceclofenac, 1923
- ACE inhibitors. *See* Angiotensin-converting enzyme (ACE) inhibitors
- Acephalgic migraine, 2560, 2589
- Aceruloplasminemia, 96e-10
- Acetaminophen
 adverse effects of
 hepatotoxicity, **2027**
 clinical features of, 2025t
 dose-related, 2028f
 liver biopsy in, 366e-4f
 pathogenesis of, 43–44
 metabolic acidosis, 320
 nephrotoxicity, 92
 thrombocytopenia, 727t
 for back pain, 118, 119t
 drug interactions of, 103e-10t, 205e-3, 2232t
 for fever, 126
 for influenza, 1214
 metabolism of, 2027
 for migraine, 2592t
 for osteoarthritis, 2231, 2232t
 overdose/poisoning with, 2027, 2764t
 for pain, 60, 91–92, 91t
 for SLE-related pain, 2132
 for spinal stenosis, 116
 for tension-type headache, 2594
 therapeutic range of, 2764t